Resumen de: US2024306636A1
This invention relates generally to cellulose nanocrystal-based emulsions that can serve as a spray adjuvant for improved agrochemical application efficiency. More particularly, the cellulose nanocrystal-based emulsions are nanocellulose-stabilized Pickering emulsions having a semi-liquid formulation of colloidal cellulose nanocrystals and biopolymers that can substitute currently used surfactants and drift reducing agents in agrochemicals. The cellulose nanocrystal-based emulsions are suitable with both water soluble and oil soluble active ingredient chemistries, and the shear characteristics of the emulsions make them suitable for oil in water-based spray applications. Droplet size distribution can be tuned by changing the ingredient concentrations, thus helping control particle drift. Moreover, a stable cross-linked network formation facilitates the entrapment and encapsulation of volatile agrochemical chemistries, thus preventing their volatilization and reducing vapor drift.
Resumen de: US2024309291A1
The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.
Resumen de: US2024307321A1
The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use.
Resumen de: US2024307318A1
Disclosed herein is a composition comprising a lipid nanoparticle and a double-stranded oligodeoxynucleotide (dsODN) encapsulated in the lipid nanoparticle. According to the embodiments of the present disclosure, the dsODN comprises two strands complementary to each other, in which the first strand comprises the nucleotide sequence of SEQ ID NO: 1. Also disclosed herein are methods of treating cancers by using the present composition.
Resumen de: US2024307308A1
There is described herein a bilayer nanovesicle comprising porphyrin-phospholipid conjugate and a chelator-fatty acid conjugate; wherein the chelator-fatty acid conjugate comprises an aminopolycarboxylic acid conjugated to a single chain fatty acid; and the porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain, preferably at the sn-1 or the sn-2 position, of one phospholipid.
Resumen de: US2024309050A1
Disclosed is a self-assembled nanoparticle containing a gHgL protein of an EB virus, a preparation method and use thereof. The self-assembled nanoparticle comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a gHgL protein and a first vector subunit, and the second polypeptide comprises a second vector subunit; the first vector subunit is 153-50A1, and the second vector subunit is 153-50B.4PT1; and the gHgL protein is linked to the first vector subunit through a linker. The gHgL protein of the EB virus is displayed on a surface of the self-assembled nanoparticle for the first time. The self-assembled nanoparticle has a larger particle size than the antigen (gHgL), a better antigen residence volume, and a thermal stability comparable to the antigen (gHgL). Moreover, since a larger number of gHgLs are displayed, the self-assembled nanoparticle can strongly stimulate more B cells and induce higher antibody titer.
Resumen de: US2024309063A1
An isoform of the TGF beta receptor II having a sequence of about of 80 amino acids and lacking a transmembrane domain. The isoform having the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2. A fusion peptide is provided having an isoform of the TGF beta II receptor fused to a ligand, wherein a vector having the fusion peptide is used to treat cancer and/or hepatic fibrosis. An antibody binding the soluble isoform of the TGF beta II receptor is provided. The antibody binds the amino acid sequence shown in SEQ ID No. 12 and is used in in vitro methods.
Resumen de: US2024308952A1
Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: US2024307521A1
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Methods of using these compositions as a vaccine for treatment of an infectious disease are also provided.
Resumen de: US2024307474A1
A botanical uni-sourced drug-loaded lipid-based nanoemulsion produced from one single medicinal herb such as Nigella sativa, Cannabis sativa, or Curcuma longa, wherein the herb acts as a comprehensive provider for the bioactive phytochemicals, oil phase, saponin surfactant, co-surfactant, proteins, and carbohydrates to produce the uni-sourced safe, clear, stable lipid-based drug delivery system. The nanoemulsion can be formulated into oral dosage form including nanoemulsion, microemulsion and liposomes, wherein the extraction and emulsification are carried out by the addition of water-soluble organic solvent, wherein the product can be further fermented and esterified for improved stability, wherein Nigella sativa uni-sourced nanocompositions are used as first-in-class oral formulation to relax coily hair targeting the arrector pili muscle in the hair root, anticancer, anti-tuberculosis, anti-COVID-19; and antiviral treatment, Cannabis nanocompositions are used for medical or recreational purposes, and Curcuma longa is used for nutraceutical and treatment purposes.
Resumen de: US2024307317A1
Hypoimmunogenic induced pluripotent stem cell (iPSC)-derived exosomes including tailored chimeric antigen receptor (CARs) which can recognize target biomarkers through an antibody fragment scFV region, bifunctional or ByTE antibodies, by a viral epitope recognition receptor (VERR), VHH nanobody, Variable New Antigen Receptor (VNAR), engineered TCR, or by any single heavy chain IgG fragment from which a variable region can be engineered. A method of making exosomes. A method of treating an individual with cancer, by administering the exosomes to an individual, targeting cancer cells, and treating the cancer. Exosomes including tailored CARs which can recognize target biomarkers through a VERR including viral receptors of an oncolytic virus. A method of treating an individual with cancer, by administering exosomes including CAR receptors having a VERR, VHH nanobody, VNAR, engineered TCR, or by any single heavy chain IgG fragment from which a variable region can be engineered with viral receptors of an oncolytic virus to an individual, targeting cancer cells, and treating the cancer. A method of targeting cells in an individual, by administering the exosomes to an individual, and targeting cells to be destroyed or treated for cancer tumors (both liquid and solid), infectious disease, hereditary conditions, autoimmune disease, or metabolic disorders.
Resumen de: US2024307358A1
The present invention provides systems for targeted delivery of therapeutic agents to Schlemm's canal (SC) endothelial cells. Also provided are methods for using the systems to treat glaucoma or reduce intraocular pressure.
Resumen de: US2024307309A1
A lipid nanoparticle composition comprising: (i) at least one zwitterionic polymer-containing lipid in which a lipid moiety is covalently attached to a zwitterionic polymer; (ii) at least one non-cationic lipid selected from charged and uncharged lipids, but not attached to a polymer; (iii) at least one cationic or ionizable lipid; and (iv) at least one therapeutic substance, and optionally (v) cholesterol or derivative thereof. Also described herein are methods of delivering a therapeutic substance to a subject, the method comprising administering to the subject a lipid nanoparticle composition described above.
Resumen de: US2024307306A1
This invention relates to a composition for ophthalmic delivery of a therapeutic agent, the composition comprising an oil-in-water (o/w) microemulsion comprising a fatty acid, or fatty acid ester, as the oil phase; an aqueous phase; a surfactant; and a co-surfactant, and wherein the composition further comprise a suspension of therapeutic agent-loaded nanoparticles. Use of the composition for the treatment or prevention of an eye disorder, a method of treatment or prevention of an eye disorder and an eye drop dispenser are also provided.
Resumen de: US2024307299A1
Provided herein are topical ophthalmic preparations which comprise a non-aqueous, self-emulsifying system which can spontaneously give rise to either nanosized emulsions upon contact with an aqueous phase. Also provided herein are methods for the preparation of the same and their use in formulating and delivering poorly water soluble drugs.
Resumen de: US2024307319A1
Disclosed in the present invention are an ionizable lipid molecule, a preparation method therefor, a composition containing same, an application thereof in the preparation of a vector for delivering a nucleic acid to a cell, and an application thereof in the preparation of a lipid nanoparticle (LNP). By improving the structure of the ionizable lipid molecule and adjusting an LNP component solution, the effect of an mRNA-LNP preparation is improved. The ionizable lipid molecule of the present invention has a structure of formula (I). The ionizable lipid molecule is synthesized with phospholipid, cholesterol, and polyethylene glycol by means of microfluidics to obtain the LNP, and the obtained LNP can improve the translation expression level of a load-mRNA in the cell, improve the effect of the mRNA-LNP preparation, and provide a theoretical basis for theoretical treatment of the personalized mRNA-LNP preparation.
Resumen de: US2024307307A1
According to one embodiment, a lipid composition is for delivering an objective substance to a target cell. The composition is contacted with the target cell under an environment of 37° C. or higher. The composition includes a substance delivery carrier having lipid particle and an objective substance encapsulated in the lipid particle. The lipid particle constitutes a liposome and includes FFT-10 and/or FFT-20 as constituents thereof.
Resumen de: US2024309366A1
Provided herein are compositions and methods for treating metabolic disorders, such as hepatic steatosis, adipose tissue dysfunction, and insulin resistance. Small interfering RNAs (siRNAs) targeting LPS-binding protein (LBP) that include unlocked nucleotides (UNA) and their therapeutic applications for the treatment of metabolic disorders are provided herein.
Resumen de: US2024309367A1
To treat disease, DNA and RNA therapeutics need to be delivered to target tissues and provide lasting benefit without side effects. Lipid nanoparticle spherical nucleic acids address this unmet need by using DNA and RNA sequences for nanoparticle targeting and tissue specificity. The lipid SNA structure has markedly different biodistribution properties than both lipid particles (loaded with nucleic acid) or even conventional SNAs (liposome and gold core).
Resumen de: US2024309382A1
Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.
Resumen de: US2024309376A1
Compositions of polynucleotide(s), pharmaceutical compositions thereof, and methods of use thereof are disclosed. A polynucleotide may be or encode a synthetic transfer ribonucleic acid (tRNA). The polynucleotide may be assembled with a lipid composition for delivery to a cell or an organ, such as a lung cell or a lung of a subject. Methods for enhancing an expression or activity of cystic fibrosis transmembrane conductance regulator (CFTR) protein in a cell are provided. Methods for treating a subject having or suspected of having a CFTR-associated condition are also provided.
Resumen de: US2024307552A1
The present disclosure provides ZnO-based compositions that stabilize mRNA and RNA as well as provide compositions and therapies to treat or prevent cancer and viral as well as microbial diseases.
Resumen de: EP4431155A2
The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and of (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm and its absolute surface charge value is of at least 10 mV (|10 mV|). The carrier is in addition devoid of any surface sterically stabilizing agent. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.
Resumen de: EP4431085A1
According to an arrangement, a lipid composition is for delivering an objective substance (3) to a target cell. The composition is contacted with the target cell under an environment of 37°C or higher. The composition includes a substance delivery carrier having lipid particle (1) and an objective substance (3) encapsulated in the lipid particle (1). The lipid particle (1) constitutes a liposome and includes FFT-10 and/or FFT-20 as constituents thereof.
Nº publicación: EP4429641A1 18/09/2024
Solicitante:
STRM BIO INCORPORATED [US]
STRM.Bio Incorporated
Resumen de: AU2022386233A1
Disclosed herein are compositions and methods related to megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells, where the megakaryocyte-derived extracellular vesicles present unique biomarkers.